A Study of TAK-861 for the Treatment of Narcolepsy Type 1

Ki vehet részt

• The participant has a body mass index (BMI) within the range 18 to 40 kilograms per meter square (kg/m\^2)
• The participant has an International Classification of Sleep Disorders, Third Edition (ICSD-3) or International Classification of Sleep Disorders, Third Edition, Text Revision (ICSD-3-TR) diagnosis of NT1
• The participant has greater than or equal to (≥)4 partial or complete episodes of cataplexy/week (WCR)
• The participant is positive for the human leukocyte antigen (HLA) genotype HLA-DQB1*06:02 or results from radioimmunoassay indicate the participant's cerebrospinal fluid (CSF) orexin (OX)/hypocretin-1 concentration is less than or equal to (≤)110 picograms per milliliter (pg/mL) [or less than one-third of the mean values obtained in normal participants within the same standardized assay]

Ki nem vehet részt

• The participant has a current medical disorder, other than narcolepsy with cataplexy, associated with EDS
• The participant: (a) has a history of myocardial infarction; (b) has a history of clinically significant hepatic disease, thyroid disease, coronary artery disease, cardiac rhythm abnormality or heart failure; or (c) has any medical condition (such as unstable cardiovascular, pulmonary, renal or gastrointestinal disease)
• The participant has current or recent (within 6 months) gastrointestinal disease that is expected to influence the absorption of drugs
• The participant has a history of cancer in the past 5 years
• The participant has a clinically significant history of head injury or head trauma
• The participant has a history of epilepsy, seizure, or convulsion
• The participant has a history of cerebral ischemia, transient ischemic attack (<5 years from screening), intracranial aneurysm, or arteriovenous malformation